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Modulation of NF-kB-dependent responses is critical
to the success of attaching/effacing (A/E) human
pathogenic E. coli (EPEC and EHEC) and the natural
mouse pathogen Citrobacter rodentium. NleB, a
highly conserved type III secretion system effector
of A/E pathogens, suppresses NF-kB activation, but
the underlying mechanisms are unknown. We identi-
fied the mammalian glycolysis enzyme glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) as an
NleB-interacting protein. Further, we discovered that
GAPDH interacts with the TNF receptor-associated
factor 2 (TRAF2), a protein required for TNF-a-medi-
ated NF-kB activation, and regulates TRAF2 poly-
ubiquitination. During infection, NleB functions as
a translocated N-acetyl-D-glucosamine (O-GlcNAc)
transferase that modifies GAPDH. NleB-mediated
GAPDHO-GlcNAcylationdisrupts theTRAF2-GAPDH
interaction to suppress TRAF2 polyubiquitination and
NF-kB activation. Eliminating NleB O-GlcNAcylation
activity attenuates C. rodentium colonization of
mice. These data identify GAPDH as a TRAF2 sig-
naling cofactor and reveal a virulence strategy em-
ployed by A/E pathogens to inhibit NF-kB-dependent
host innate immune responses.
INTRODUCTION
Enterohemorrhagic E. coli (EHEC) are attaching/effacing (A/E)
pathogens that are especially detrimental to human health
because they cause hemorrhagic colitis and a type of renal
failure (hemolytic uremic syndrome, HUS) for which therapy is
limited. A related E. coli virotype, enteropathogenic E. coli
(EPEC), is an important cause of infantile diarrhea. These human
pathogens, as well as Citrobacter rodentium, a mouse pathogen
that shares virulence strategies with E. coli (Deng et al., 2003),
translocate virulence proteins (effectors) into intestinal epithelial
cells using a type III secretion system (T3SS) to subvert the
activity of various cell functions (Dean and Kenny, 2009).Cell HE. coli and C. rodentium T3SS effectors modulate the innate
immune system, including host responses regulated by the tran-
scription factor NF-kB, via several different mechanisms (Rah-
man andMcFadden, 2011). TheNleBeffector is highly conserved
among the A/E pathogens (Kelly et al., 2006). NleB-deficient
C. rodentium do not cause mortality (Wickham et al., 2007) or
significant colonic hyperplasia (Kelly et al., 2006) in mice. These
bacteria show markedly reduced colonization, as compared
with wild-type (WT) C. rodentium, indicating the importance of
NleB to C. rodentium virulence. NleB is associated with human
EHEC outbreaks and the subsequent development of HUS
(Wickham et al., 2006). The presence of NleB in atypical EPEC
strains is associated with diarrheal disease (Bugarel et al.,
2010). Thus, NleB plays an important role in the virulence of A/E
pathogens. Two recent studies determined thatNleB suppresses
NF-kB activation (Nadler et al., 2010; Newton et al., 2010).
Here, we characterize a mechanism by which NleB inhibits
NF-kB signaling. NleB functions as a translocated N-acetyl-
D-glucosamine (O-GlcNAc)-transferase that modifies the
mammalian glycolysis enzyme glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). We provide evidence that GAPDH is
a coactivator of the TNF receptor-associated factor 2 (TRAF2)
and that NleB-mediated GAPDH O-GlcNAcylation inhibits both
TRAF2 activation and downstream NF-kB signaling.
RESULTS
NleB Inhibits NF-kB Activation by Inhibiting TRAF2
Polyubiquitination
WT C. rodentium colonized C57BL/6J mice to a greater
magnitude than a strain bearing an isogenic deletion of NleB
(DnleB; see Figure S1A online). Complementing DnleB C. roden-
tium with a FLAG-tagged NleB expression plasmid (DnleB/
pnleB) restored bacterial colonization to nearly WT levels. WT
C. rodentium was shed in mouse feces in greater numbers
over the duration of infection, as compared with DnleB C. roden-
tium (Figure S1B). TNF serum concentrations were significantly
higher in mice infected with WT C. rodentium than in mice in-
fected with DnleB (Figure 1A), indicating that NleB contributes
to bacterial-induced host inflammation.
NleB inhibits tumor necrosis factor (TNF)-induced NF-kB
activation (Newton et al., 2010; Nadler et al., 2010), but itsost & Microbe 13, 87–99, January 16, 2013 ª2013 Elsevier Inc. 87
Figure 1. NleB Inhibits NF-kB Activation by
Preventing TRAF2 Polyubiquitination
(A) TNF concentrations (pg/ml; mean ± SEM, n = 8)
in serum (7 days postinfection) from uninfected
mice or mice infected with indicated C. rodentium
strains. Asterisks indicate significantly different
[TNF] as compared with WT infection (one-way
ANOVA with Bonferonni’s multiple comparison
test).
(B) TRAF2-FLAG was cotransfected with NleB-
HA and immunoprecipitated using a-FLAG anti-
body. Immunoprecipitates were immunoblotted
for FLAG, TRADD, ubiquitin, and HA. LC, antibody
light chain.
(C) HeLa cells were transfected with TRAF2-FLAG
and then infected with C. rodentium for 1 or 3 hr.
TRAF2 and IkBa abundance were analyzed using
immunoblotting.
(D) HeLa cells were transfected with either TRAF2-
FLAG or DRING TRAF2 (TRAF2-RM) plasmids and
then infected with C. rodentium for 3 hr.
(E) HeLa cells were transfected with TRAF2-FLAG,
pretreated with 10 mM MG-132 for 2 hr, and then
infected with C. rodentium. TRAF2 was immuno-
precipitated, and polyubiquitination was assessed
using immunoblotting.
(F) RIP1 was cotransfected with NleB-HA and
immunoprecipitated using a-RIP1 antibody. Immu-
noprecipitates were immunoblotted for ubiquitin
and RIP1. Data are represented as mean ± SEM,
n =3.Asterisks indicate significantly different [RIP1-
Ub] as compared with TNF treatment (Bonfer-
onni’s).
See also Figure S1.
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NleB-HA, stimulated these cells with TNF, and subsequently
examined the extent of degradation of the NF-kB inhibitor,
IkBa. NleB prevented TNF-induced IkBa degradation, as well
as the subsequent translocation of the NF-kB p65 subunit to
the nucleus (Figure S1C).
Deleting nleB from C. rodentium did not significantly alter nleE
expression, another effector that inhibits NF-kB activation (Fig-
ure S1D; Nadler et al., 2010). Both NleB and NleE, when trans-
fected into HeLa cells, inhibited TNF-induced IkBa degradation
(Figure S1E). Neither DnleB nor DnleE C. rodentium prevented88 Cell Host & Microbe 13, 87–99, January 16, 2013 ª2013 Elsevier Inc.IkBa degradation during infection, by
contrast to WT C. rodentium (Fig-
ure S1F), indicating a potential coordi-
nated activity between the effectors
during C. rodentium infection.
After TNF stimulation, the cytosolic
death domain of the TNF receptor-1
(TNFR1) recruits proteins such as the
TNFR-associated death domain protein
(TRADD), TRAF2, and the receptor-inter-
acting protein 1 (RIP1) to form complexes
that activate the NF-kB pathway
(Chen and Goeddel, 2002). During this
process, TRAF2, an E3 ubiquitin ligase,
becomes polyubiquitinated and activatesRIP1 kinase activity. TRAF2 polyubiquitination was induced
by TNF in control cells (Figure 1B), whereas cells transfected
with NleB-HA exhibited significantly reduced TRAF2 poly-
ubiquitination. The TRAF2 interaction partner TRADD was still
recruited to TRAF2 in NleB-transfected cells, suggesting that
the method by which NleB inhibits TRAF2 polyubiquitination is
independent of TRADD.
Bacterial infection induces production of additional TNFR
ligands, including RANKL and CD40L (Zheng et al., 2008). These
molecules can not only cause TRAF2 polyubiquitination, but also
can promote its degradation. We transfected HeLa cells with
Cell Host & Microbe
NleB Glycosylates GAPDH to Inhibit TRAF2/NF-kBTRAF2-FLAG and then infected these cells with C. rodentium
strains that either express or lack NleB. Infecting cells withC. ro-
dentium DnleB induced TRAF2 degradation (Figure 1C), with
almost complete degradation of TRAF2 observed after 3 hr. By
contrast, TRAF2 was stable in cells infected with either WT or
DnleB/pnleB C. rodentium (Figure 1C). TRAF2 degradation was
mediated by ubiquitination, as DnleB C. rodentium failed to
induce the degradation of a TRAF2 DRING mutant (Figure 1D).
Treating cells with the 26S proteasome inhibitor MG-132 also
stabilized TRAF2 during infection (Figure 1E).
We hypothesized that NleB might target the TRAF2 poly-
ubiquitination normally induced upon TNFR stimulation. TRAF2
polyubiquitination was prevented in cells infected with either
WT or DnleB/pnleB C. rodentium, but not DnleB C. rodentium
(Figure 1E). NleB also inhibited the ubiquitination of RIP1,
a substrate of TRAF2 Ub ligase activity (Alvarez et al., 2010; Fig-
ure 1F). However, NleB did not directly inhibit TRAF2 self-ubiqui-
tination in vitro (Figure S1G). Overall, our data instead suggested
that NleB might target an unidentified coactivator(s) of TRAF2 to
prevent its polyubiquitination either upon TNFR stimulation or
after bacterial infection, subsequently attenuating NF-kB
activation.
NleB Interacts with GAPDH
We did not obtain evidence that NleB interacts with TRAF2 from
immunoprecipitation experiments (Figure 1B). We conducted
a proteomic screen to identify NleB interaction partner(s) by puri-
fied NleB-FLAG (Figure 2A) and used it in affinity column exper-
iments to identify a human protein of 37 kDa that interacted
with NleB (Figure 2B). By usingmass spectrometry and immuno-
blotting affinity-purified cell lysates, we identified this protein as
human GAPDH (Figures 2C and 2D), a component of the glycol-
ysis pathway.
GAPDH coimmunoprecipitated ectopically expressed NleB-
HA, but not an HA-epitope control (Figure 2E). Infecting HeLa
cells with C. rodentium strains expressing either NleB or NleC
(an effector that also targets the NF-kB pathway; Pearson
et al., 2011) showed that NleB, but not NleC, immunoprecipi-
tated with GAPDH during C. rodentium infection (Figure 2F).
We then developed an in vitro pull-down assay with purified re-
combinant proteins. NleB-FLAG, but not NleC-FLAG, binds
directly to GAPDH (Figure 2G), as NleB-FLAG was pulled down
in vitro when mixed with GAPDH.
We quantified the affinity of the NleB-GAPDH interaction
in vitro by performing ELISAs. NleB-FLAG bound to immobilized
GAPDH with an apparent dissociation constant (Kd) of 32 ± 6 mM
(Figure 2H). By contrast, NleC-FLAG did not bind GAPDH with
significant affinity. We did not detect significant changes in the
abundance or in the cytoplasmic localization of GAPDH as
a function of expressing NleB (data not shown).
Some apoptotic stimuli generate nitric oxide, which subse-
quently causes GAPDH to be S-nitrosylated on its catalytic
cysteine (C150) residue (Hara et al., 2005). We found that both
WT and a C150S GAPDH mutant protein bound directly to
NleB in vitro (Figure 2I). Likewise, treating GAPDH with iodoace-
tate (IA), a small-molecule inhibitor that modifies the GAPDH
C150 sulfhydryl moiety and prevents disulfide bond formation
(Harrison et al., 2003), at a concentration sufficient to inhibit
GAPDH enzyme activity (10 mM; Figure 2J), did not disrupt theCell HGAPDH-NleB interaction in vitro (Figure 2K). NleB binding to
GAPDH did not inhibit GAPDH enzyme activity (Figure 2J), either
alone or in concert with IA, indicating the NleB-GAPDH interac-
tion is unlikely to affect host glycolysis directly. Overall, our data
suggest that GAPDH is a eukaryotic interaction partner for NleB
and that this interaction is independent of GAPDH C150.
GAPDH Is Required for TNF-Induced NF-kB Activation
The role of GAPDH in stress response pathways has been
studied previously (Hara et al., 2005). GAPDH participates in
NF-kB signaling (Bouwmeester et al., 2004; Mookherjee et al.,
2009), but the precise mechanism has not been elucidated.
Transfecting siRNAs targeting the GAPDH-30UTR GAPDH
depleted GAPDH abundance by 50% (Figure S2A) and acti-
vated multiple stress-induced signaling pathways (Figure S2B),
possibly due to the generation of reactive oxygen species
(ROS; Figure S2C) and the release of cytochrome c from mito-
chondria (Figure S2D). Complementing GAPDH knockdown
cells with either WT or C150S GAPDH-Myc prevented cyto-
chrome c release (Figure S2D) and reduced NF-kB pathway acti-
vation (Figures S2E and S2F).
Complementing GAPDH knockdown cells with a GAPDH
K160R plasmid, which encodes a form of GAPDH that cannot
be acetylated by the p300/CREB binding protein (CBP; Sen
et al., 2008), did not inhibit TNF-induced IkBa degradation (Fig-
ure S2E). The K160 residue is essential for GAPDH binding to
p300/CBP in the nucleus, an interaction that subsequently acti-
vates downstream apoptotic events. Because initiation of
apoptosis typically leads to NF-kB pathway activation (Van Ant-
werp et al., 1996), we conclude that K160 is not likely to be
involved in TNF/NF-kB signaling under the conditions of our
assays.
By contrast to WT and K160R GAPDH, complementing
GAPDH knockdown cells with GAPDH C150S resulted in an
30% reduction in cellular ATP levels (Figure S2G). This 30%
reduction in [ATP] is not likely to contribute to the attenuation
of NF-kB activation, as a larger reduction in [ATP] was observed
by inhibiting the rate-limiting glycolytic enzyme, pyruvate kinase,
with potassium oxalate (PO; Figure S2H). However, pyruvate
kinase inhibition only caused a mild attenuation of TNF-induced
NF-kB activation (Figure S2I).
We hypothesized that GAPDH enzyme activity might be
required for NF-kB activation after TNF stimulation. Whereas
complementation with WT GAPDH only slightly enhanced NF-
kB activation, complementation with GAPDH C150S instead
significantly attenuated NF-kB activation after TNF treatment
(Figure 3A). AP-1 luciferase activity was independent of GAPDH
enzyme activity (Figure 3B), suggesting a degree of specificity of
GAPDH to the NF-kB pathway. Expressing GAPDHC150S failed
to restore TNF-induced IKKb phosphorylation in GAPDH knock-
down cells (Figure 3C). We concluded that WT GAPDH is
required for TNF-induced NF-kB activation.
We used a pharmacological approach to evaluate the role of
glycolysis on TNF-induced NF-kB activation. We first pretreated
HeLa cells with IA to inhibit GAPDH and then treated these cells
with TNF. While IA targets many other proteins containing reac-
tive cysteines, including deubiquitinating peptidases, a number
of other studies have used this reagent to inhibit both GAPDH
and glycolysis (Fujiki et al., 2011; Wentzel et al., 2003). We alsoost & Microbe 13, 87–99, January 16, 2013 ª2013 Elsevier Inc. 89
Figure 2. NleB Binds GAPDH
(A) NleB-FLAG protein purity assessed by Coomassie blue staining after 12% SDS-PAGE.
(B) HeLa cell lysates were incubated with purified NleB-FLAG prebound to FLAGM2 beads and analyzed by SDS-PAGE. The band indicated with an asterisk was
excised and analyzed using mass spectrometry.
(C) GAPDH amino acid sequence. Tryptic peptides identified by mass spectrometry are indicated in bold.
(D) Affinity column samples were analyzed using immunoblotting with a-GAPDH antibody.
(E) NleB-HA was transfected. GAPDH was immunoprecipitated and immunoblotted for GAPDH and HA.
(F) Immunoprecipitation of GAPDH from HeLa cells by translocated NleB- or NleC-FLAG after C. rodentium infection for 0.5, 1, or 3 hr. Samples were immu-
noprecipitated with a-GAPDH antibody and immunoblotted for FLAG and GAPDH.
(G) FLAG-tagged NleB or NleC was coupled to M2 beads and incubated with GAPDH. Samples were analyzed using IRDye blue protein staining after elec-
trophoresis through 12% SDS-PAGE.
(H) ELISA plates were coated with 2 mgGAPDH. Coated plates were overlaid with increasing amounts of NleB- or NleC-FLAG. Protein binding was detected using
a-FLAG antibody and 1-Step Ultra TMB-ELISA solution. Absorbance at 450 nm was measured (mean ± SEM, n = 4).
(legend continued on next page)
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Figure 3. GAPDH Is Essential for TNF-Induced NF-kB Activation
(A) NF-kB luciferase activity as a function of GAPDH complementation (mean ±
SEM, n = 3). Asterisks indicate significantly different luciferase activity
between GAPDH WT and C150S complementation (t test).
(B) AP-1 luciferase activity as a function of GAPDH complementation (mean ±
SEM, n = 3).
(C) Analysis of IKKb phosphorylation and IkBa degradation in GAPDH
knockdown cells complemented with WT GAPDH or GAPDH C150S. HeLa
cells were cotransfected with GAPDH siRNA, as well as with IKKb-FLAG and
either WT GAPDH-Myc or GAPDH-C150S-Myc plasmids, and then stimulated
with TNF.
See also Figure S2.
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NleB Glycosylates GAPDH to Inhibit TRAF2/NF-kBpretreated cells with two other drugs that target glycolytic
enzymes, either a pyruvate kinase inhibitor, PO, or a hexokinase
inhibitor, 2-deoxy-D-glucose (2DG). Treating cells with either
PO or with 2DG depleted [ATP] to 20% of that detected in
untreated cells (Figure S2H). By contrast, IA treatment only
reduced [ATP]s 2-fold. However, IA significantly inhibited
GAPDH enzyme activity, whereas both 2DG and PO had less
impact (Figure S2J).
Following TNF treatment, we conducted gene expression
analyses. Our microarray (data not shown) and RT-PCR assays
(Figure S2K) showed that IA significantly inhibited TNF-induced
increases in the expression of numerous NF-kB-regulated(I) In vitro pull-down assay for the interaction between GAPDH C150S and Nl
NleB-FLAG or NleC-FLAG proteins prebound to M2 beads.
(J) GAPDH enzyme inhibition by iodoacetate (IA; mean ± SEM, n = 3). Asterisks
(K) Impact of IA onGAPDH-NleB bindingwasmeasured using in vitro pull-down as
to M2 beads.
Cell Hgenes. By contrast, neither 2DG nor PO significantly reduced
the NF-kB-dependent gene expression normally induced by
TNF. We reached similar conclusions by studying NF-kB lucif-
erase reporter activation after inhibitor treatment (Figure S2I).
By contrast to the NF-kB-regulated genes, the expression of
NF-kB-independent genes was not impaired by drug treatment
(Figure S2K), again suggesting a degree of specificity for GAPDH
activity in the NF-kB pathway.
Likewise, TNF failed to induce IkBa degradation and IKKb
phosphorylation in IA-treated cells but had normal activity in cells
treated with either PO or with bromopyruvate (BP), a hexokinase
inhibitor (Figure S2L). Both p38 and JNK phosphorylation were
unaffected by IA (Figure S2L). These data suggest that GAPDH
regulates the NF-kB signaling pathway using a mechanism
distinct from its enzymatic role in glycolysis.
GAPDH Binds and Activates TRAF2
TRAF2 is structurally similar to the E3 ligase Siah1, which inter-
acts with GAPDH under stress (Hara et al., 2005). To determine
whether GAPDH interacts with TRAF2, we cotransfected
TRAF2-FLAG with GAPDH-Myc and then immunoprecipitated
TRAF2-FLAG. WT GAPDH was associated with TRAF2, and
this interaction was enhanced by TNF (Figure 4A). The associa-
tion of endogenous GAPDH with TRAF2 was also promoted by
TNF (Figure 4B). Using in vitro pull-down assays with TRAF2-
His, NleB-FLAG, and recombinant GAPDH, we determined that
TRAF2 interacts directly with GAPDH, but not with NleB (Fig-
ure 4C). GAPDH C150S did not immunoprecipitate with TRAF2
(Figure 4A), suggesting the importance of the C150 residue for
the interaction between GAPDH and TRAF2 in vivo. TRAF2
bound to WT GAPDH with an apparent Kd of 96 ± 31 mM (Fig-
ure 4D). TRAF2 did not bind to GAPDH C150S with significant
affinity.
We investigated whether the GAPDH-TRAF2 interaction is
important for TRAF2 activity in response to TNF. After transfect-
ing GAPDH siRNA and GAPDH-Myc plasmids, we treated cells
with TNF and immunoprecipitated TRAF2. TRAF2 poly-
ubiquitination was enhanced in cells expressing WT GAPDH
(Figure 4E), whereas TRAF2 polyubiquitination was attenuated
either in cells complemented with GAPDH C150S or in cells
treated with IA. This phenotype appears to be unrelated to
cellular ATP levels, as treating cells with PO (Figure 4E, lane 4),
which significantly reduced ATP stores (Figure S2H), did not
impair TRAF2 polyubiquitination. Thus, GAPDH binds TRAF2,
its recruitment is dependent upon the C150 residue, and the
interaction is enhanced by TNF.
NleB Is a Glycosyltransferase that O-GlcNAcylates
GAPDH
Analysis of the NleB amino acid sequence using the HHPred/
HHSearch package (So¨ding et al., 2005) revealed that the central
region of NleB is significantly similar (p value 107) to GT-8
family glycosyltransferases. These glycosyltransferases have aeB. Purified GAPDH- and GAPDH C150S-His proteins were incubated with
indicate significantly different GAPDH activity (Bonferroni’s).
say. GAPDHwas treatedwith IA and then incubated with NleB-FLAG prebound
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Figure 4. GAPDH Interacts with TRAF2
(A) HeLa cells were transfected with TRAF2-
FLAG ± GAPDH-Myc plasmids, immunoprecipi-
tated using a-FLAG antibody, and then immuno-
blotted using a-Myc antibody.
(B) Experiment was performed as described in (A),
except that endogenous GAPDH association with
TRAF2 was monitored using a-GAPDH antibody.
TNF treatment time is indicated.
(C) TRAF2-His protein was coupled to Ni-NTA
agarose and incubated with GAPDH and/or NleB-
FLAG ± 1.0 mM UDP-GlcNAc. The bound and
flowthrough (FT) samples are indicated.
(D) ELISA plates were coated with 2 mg of either
WT GAPDH or C150S GAPDH. Coated plates
were overlaid with increasing amounts of TRAF2.
Protein binding was detected using a-TRAF2
antibody (mean ± SEM, n = 4).
(E) HeLa cells were transfected and treated 60 hr
later with indicated glycolysis enzyme inhibitors.
Cell lysates were immunoprecipitated using
a-FLAG antibody to capture TRAF2-FLAG and
immunoblotted for ubiquitin and GAPDH-Myc.
Additional immunoprecipitations were conducted
using a-Myc antibody to captureGAPDH-Myc and
immunoblotted for O-GlcNAc and OGT.
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sented by either a canonical or by a modified Rossman fold.
These proteins are also characterized by a DxD catalytic signa-
ture, which chelates the divalent cation implicated in catalysis
(Liu and Mushegian, 2003). The DxD signature, in the form of
DAD tripeptide, is present in all NleB homologs we examined,92 Cell Host & Microbe 13, 87–99, January 16, 2013 ª2013 Elsevier Inc.as well as in the most closely related
glycosyltransferases within the GT-8
family, namely the eukaryotic glycoge-
nins (Figure S3A).
Glycogenins are glycosyltransferases
that attach glucose to the growing
glycogen chain (Lazarus et al., 2011).
Multiple sequence alignments indicated
the conservation of several b strands
and connecting a helices that form the
modified Rossmann fold in the glycoge-
nin structure (Figure S3A). Particularly
well conserved are two b strands con-
nected by the loop in which the con-
served catalytic DxD motif is located, as
well as the upstream motif between
two a helices that makes direct contacts
to the uridine diphosphate (UDP), the
dinucleotide substrate of human glyco-
genin 1.
In eukaryotic cells, O-linked-N-acetyl-
glucosamine (O-GlcNAc) regulates
numerous cellular signaling networks,
including the NF-kB pathway (Yang
et al., 2008), often in opposition with pro-
tein phosphorylation. O-GlcNAc trans-
ferase (OGT) and O-GlcNAcase (OGA)regulate protein O-GlcNAcylation (Hart et al., 2011). OGT cata-
lyzes the transfer of N-acetylglucosamine from UDP-GlcNAc to
the hydroxyl oxygen of serine or threonine, whereas OGA
removes O-GlcNAc from targeted proteins.
We used an O-GlcNAc in vitro labeling assay to determine
whether NleB possess glycosyltransferase activity. a-crystallin,
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lated, was used as a positive control. We incubated purified
NleB-FLAG with GAPDH in the presence of UDP-GlcNAc and
discovered that NleB-FLAG is capable of O-GlcNAcylating
GAPDH (Figure 5A). We confirmed these data by using an anti-
body (110.6) that specifically recognizes O-GlcNAcylation sites
on proteins (Figure 5B). The intensity of NleB-mediated GAPDH
O-GlcNAcylation was proportional to the concentration of the
sugar nucleotide donor UDP-GlcNAc (Figure 5C).
To investigate whether NleB O-GlcNAcylates GAPDH during
bacterial infection, we infected HeLa cells for 3 hr with
C. rodentium. GAPDH O-GlcNAcylation was induced in cells in-
fected with WT C. rodentium, but not in cells infected with DnleB
C. rodentium (Figure 5D). GAPDH was not O-GlcNAcylated in
control cells or in cells treated only with TNF (Figure 5E).
However, after transfecting NleB-HA, GAPDH was modified
with O-GlcNAc (Figure 4E and Figure 5E). NleB also O-GlcNAcy-
lated GAPDH C150S in vivo (Figure 4E) and in vitro (Figure 5F),
consistent with results suggesting GAPDH C150 is not required
for the GAPDH-NleB interaction.
To begin to identify GAPDH O-GlcNAcylation sites, we first
considered several GAPDH residues that are modified by
cellular enzymes. Although we did not detect OGT in TRAF2-
GAPDH complexes (Figure 4E), OGT has been suggested to
O-GlcNAcylate GAPDH on T229 (Park et al., 2009). We mutated
T229 (T229A) and a neighboring threonine residue, T211 (T211A),
to determine if NleB targets them for modification. However,
neither mutant differed in NleB-mediated GAPDH O-GlcNAcyla-
tion (Figure 5F). GAPDH is phosphorylated by protein kinase B
(AKT) on T237, which prevents GAPDH nuclear translocation
and suppresses GAPDH-mediated apoptosis (Huang et al.,
2011). We also mutated T237 (T237A), as well as the neighboring
residues S241 (S241A), T246 (T246A), and T277 (T277A).
However, we still did not detect significant changes to NleB-
mediated GAPDH O-GlcNAcylation, indicating there may be
other or multiple GAPDH residues targeted by NleB (Figure 5F).
To confirm further that NleB is an O-GlcNAc transferase,
we mutated the predicted catalytic site 221DAD223 of NleB
to 221AAA223. The NleB 221DAD-AAA223 mutant (hereafter desig-
nated NleB(AAA)) failed to O-GlcNAcylate GAPDH proteins
either in vivo (Figure 4E and Figure 5E) or in vitro (Figure 5G).
Expressing an NleB mutant in which the modified Rossmann
fold was deleted (D202) also abolished the O-GlcNAcylation of
GAPDH by NleB (Figure 5G). However, GAPDH, in the presence
or absence of NleB and UDP-GlcNAc, did not directly inhibit
TRAF2 self-ubiquitination in vitro (Figure S3B).
O-GlcNAcase catalyzes the cleavage of O-GlcNAc from
glycosylated proteins. Treating cells with an O-GlcNAcase
inhibitor, thiamet G (TMG), increased total cellular protein O-
GlcNAcylation (Figure 5E). We tested whether O-GlcNAcylation
of GAPDH by NleB is enhanced by TMG treatment. Although
we did not detect any basal GAPDH O-GlcNAcylation in our
experimental system, we found that GAPDH O-GlcNAcylation
was significantly enhanced by NleB (Figure 5E) and further
enhanced after TMG treatment. By contrast, the NleB(AAA)
mutant failed to induce GAPDH O-GlcNAcylation, irrespective
of TMG. Thus, NleB activity appears to be linked to cellular
O-GlcNAc concentrations. These experiments were conducted
using ectopic expression of NleB andNleB(AAA) to allow specificCell Hanalysis of the TNF/TRAF2 pathway, in the absence of other
potential inducers generated during bacterial infection (e.g.,
IL-1b, LPS).
Most proteins that are O-GlcNAcylated by OGT are sensitive
to glucose concentrations because this sugar affects the activity
of the hexosamine biosynthetic pathway (Hart et al., 2011). In our
system, total protein O-GlcNAcylation was decreased in cells
cultured in hypoglycemic conditions, as compared with hyper-
glycemic conditions (Figure S3C). However, the level of GAPDH
O-GlcNAcylation mediated by NleB did not change significantly
in the different glucose conditions (Figure S3D), indicating that
the activity of NleB may be largely insensitive to changes in
UDP-GlcNAc concentrations. Taken together, our data suggest
that NleB is a translocated glycosyltransferase thatmodifies host
GAPDH with O-GlcNAc.
NleB O-GlcNAc Transferase Activity Disrupts the
GAPDH-TRAF2 Interaction and Inhibits NF-kB Activity
We immobilized TRAF2-His on Ni-NTA agarose and then applied
either purified GAPDH or NleB-FLAG ± UDP-GlcNAc to assess
the binding interactions among these three proteins. More
NleB-FLAG was pulled down by GAPDH/TRAF2 in the absence
ofUDP-GlcNAc thanwhenUDP-GlcNAcwaspresent (Figure 6A).
When incubated with NleB and UDP-GlcNAc, only the GAPDH
that had dissociated from TRAF2 possesses a significant O-
GlcNAcylation signal, as compared with GAPDH still bound to
TRAF2 (Figure 6B). We therefore hypothesized that NleB might
interact with GAPDH to disrupt the formation of TRAF2-GAPDH
complex through its O-GlcNAc transferase activity. Indeed, while
WT NleB blocked the association of GAPDH with TRAF2 after
TNF treatment, the glycosyltransferase-deficient mutant Nle-
B(AAA) failed to do so (Figure 4E).
GAPDH that had been previously labeled in vitro with O-
GlcNAc by NleB had significantly lower affinity for TRAF2, as
compared with unlabeled GAPDH (Figure 6C), while adding
excess UDP-GlcNAc to the ELISA had no discernible impact
on TRAF2-GAPDH affinity (Figure 6C). Thus, the glycosyltrans-
ferase activity of NleB appears to disrupt the TRAF2-GAPDH
interaction, as GAPDH O-GlcNAcylation by NleB significantly
reduced the affinity between GAPDH and TRAF2 in vitro (Fig-
ure 6) and prevented their association in vivo (Figure 4).
We next examined whether NleB-mediated GAPDHO-GlcNA-
cylation is essential for NleB to inhibit NF-kB pathway activation.
By contrast to WT NleB, NleB(AAA) did not prevent IkBa degra-
dation stimulated by TNF (Figure 5E). NleBD202 mutant also
failed to block IkBa degradation and p65 nuclear translocation
(Figure 6D). These data are consistent with our findings that
TRAF2 polyubiquitination was not impaired by the glycosyltrans-
ferase-deficient mutant NleB(AAA) upon TNF stimulation, in
contrast with WT NleB (Figure 4D and Figure 5E).
WT NleB completely abolished TRAF2 polyubiquitination
induced by TNF in TMG-treated cells, whereas NleB(AAA) had
no impact (Figure 5E, lane 7 versus lane 8). Although TMG treat-
ment alone did not prevent IkBa degradation and NF-kB activa-
tion, it stabilized IkBa in the presence of WT NleB, but not in the
presence of NleB(AAA) (Figure 5E). NleB exhibited a more robust
inhibition of NF-kB in cells treated with TMG as compared with
cells not treated with TMG (Figure 6E). NF-kB activity was
promoted by TMG treatment, consistent with previous reportsost & Microbe 13, 87–99, January 16, 2013 ª2013 Elsevier Inc. 93
Figure 5. NleB O-GlcNAcylates GAPDH
(A) Detection of GAPDH O-GlcNAcylation by NleB using 5-carboxytetramethylrhodamine (TAMRA).
(B) Detection of GAPDH O-GlcNAcylation by NleB using a-O-GlcNAc antibody (110.6).
(C) GAPDH O-GlcNAcylation as a function of [UDP-GlcNAc]. NleB- or NleC-FLAG was incubated with GAPDH and UDP-GlcNAc. Proteins were analyzed by
SDS-PAGE and immunoblotted for the O-GlcNAcylation using a-GlcNAc antibody.
(D) GAPDH O-GlcNAcylation during bacterial infection. HeLa cells were infected with C. rodentium WT or DnleB for 1 or 3 hr. Cell lysates were immunopre-
cipitated with a-GAPDH antibody and analyzed for O-GlcNAcylation. Asterisks indicate other proteins detected in GAPDH immunoprecipitates more heavily
O-GlcNAcylated in the presence NleB.
(legend continued on next page)
Cell Host & Microbe
NleB Glycosylates GAPDH to Inhibit TRAF2/NF-kB
94 Cell Host & Microbe 13, 87–99, January 16, 2013 ª2013 Elsevier Inc.
Cell Host & Microbe
NleB Glycosylates GAPDH to Inhibit TRAF2/NF-kB(Kawauchi et al., 2009). Neither NleB nor TMG altered AP-1
activation (Figure 6F), indicating that NleB-mediated GAPDH
O-GlcNAcylation is specifically involved in the NF-kB signaling
pathway.
To evaluate whether the O-GlcNAc transferase activity of NleB
is important to C. rodentium virulence, we infected mice with
C. rodentium strains expressing either WT NleB (DnleB/pnleB)
or the O-GlcNAc transferase-deficient NleB mutant, NleB(AAA)
(DnleB/pnleB(AAA)). Mice infected with DnleB/pnleB(AAA)
C. rodentium strain showed an 100-fold reduction in coloniza-
tion magnitude after 7 days, as compared with C. rodentium
expressingWTNleB (Figure 6G). While the reduction in coloniza-
tion was not as great compared with the impact of deleting the
entire nleB gene, this result demonstrated that a major role of
C. rodentium host colonization mediated by NleB is due to its
O-GlcNAc transferase activity.
Consistent with this phenotype, the NleB(AAA) mutant failed to
suppress NF-kB activation during C. rodentium infection of HeLa
cells, as compared with WT and DnleB/pnleB C. rodentium, even
in the absence of exogenous TNF (Figure 6H). Overexpressing
GAPDH ectopically in cells that were subsequently infected with
C. rodentium strains expressing NleB was able to restore partially
NF-kB luciferase activity (Figure 6H). By contrast, GAPDH overex-
pressiondidnot increaseNF-kBactivity incells infectedwithDnleB
C. rodentium, suggesting a potential saturation of the interaction
betweenGAPDHandendogenousTRAF2.BecauseGAPDHover-
expression also did not significantly increase basal NF-kB activity
inuninfectedcells,ourdatasuggest that theO-GlcNActransferase
activity of NleB is essential for its ability to inhibit NF-kB activation
and to enhance C. rodentium colonization and virulence through
a mechanism involving the modification of GAPDH (Figure 7).
Further, these data suggest that GAPDH might play a role as
a general stress sensor by participating in NF-kB signaling.
DISCUSSION
Several studies have suggested that GAPDH may be involved in
regulating innate immunity. GAPDH is enriched with the NF-kB
family member c-Rel and with other NF-kB signaling molecules
(Bouwmeester et al., 2004). Mookherjee et al. also predicted
that GAPDH interacts with molecules in the NF-kB pathway
(Mookherjee et al., 2009). GAPDH binding to TRAF2 was
enhanced under stress conditions, similar to the interaction
between Siah1 and GAPDH (Hara et al., 2005). Our data suggest
that GAPDH may be a coactivator of TRAF2, perhaps acting at
an early step in the TNF/NF-kB signaling pathway, before E1
and E2 enzymes are recruited to TRAF2. How GAPDH facilitates
TRAF2 polyubiquitination is unknown and will require significant
future structure-function experiments. We raise the possibility
that there may be a network of factors recruited to TRAF2(E) NleB(AAA) does not O-GlcNAcylate GAPDH. HeLa cells were cotransfected
TMG for 8 hr ± TNF (20 s). Cell lysates were immunoprecipitated for TRAF2-F
O-GlcNAcylation.
(F) Purified GAPDH mutant proteins were incubated with NleB-FLAG and UDP
GAPDH and NleB proteins were analyzed using IRDye blue protein staining. The
were not assayed for GAPDH O-GlcNAcylation.
(G) FLAG-NleBWT andmutants were purified and incubated with WTGAPDH. Sa
a-GAPDH antibodies.
See also Figure S3.
Cell Hupon TNFR stimulation that is important to regulating TRAF2
activation, among these, GAPDH.
While TNF activates the NF-kB, p38, and JNK signaling path-
ways through TRAF2, the role of TRAF2 ubiquitination is more
essential to downstream JNK than to either p38 or NF-kB
signaling (Habelhah et al., 2004), possibly due to the redundant
role of TRAF2 and TRAF5 in NF-kB activation (Tada et al.,
2001; Yeh et al., 1997). Our data show that GAPDH-mediated
TRAF2 ubiquitination is required for NF-kB activation, but not
for JNK and p38 activation. GAPDH may catalyze a specific
form of TRAF2 ubiquitination or may promote a different modifi-
cation that somehow enhances the TRAF2 polyubiquitination
activity required for downstream NF-kB activation.
We found that the GAPDH C150 residue is essential to the
GAPDH-TRAF2 interaction. This is consistent with previous
work, which also showed that C150 is involved in the GAPDH
activities that are independent of glycolysis (Hara et al., 2005).
Although it is not clear how C150 contributes to GAPDH involve-
ment in these processes, this active site residue is redox sensi-
tive and is often modified under stress conditions.
Various studies have also shown that cellular signaling and
protein glycosylation are tightly linked (Wellen and Thompson,
2012). O-GlcNAcylation requires UDP-GlcNAc, the final product
of the hexosamine biosynthetic pathway. Evidence that O-
GlcNAcylation is important in regulating immune signaling
pathways is emerging. Enhanced glucose metabolism induces
O-GlcNAcylation of NF-kB components and increases NF-kB
activity (Kawauchi et al., 2009; Yang et al., 2008). For example,
O-GlcNAcylation of TAB1 after IL-1b stimulation is essential for
TAK1 activation and NF-kB activation (Pathak et al., 2012). In
agreement with these studies, we found that inhibiting OGA
increased NF-kB activity after TNF stimulation.
We showed that GAPDH is O-GlcNAcylated by the T3SS
effector NleB, a glycogenin-related glycosyltransferase. O-
GlcNAcylated GAPDH fails to interact with TRAF2 in vivo.
GAPDH O-GlcNAcylation by OGT on T227 has been reported
before (Park et al., 2009). However, we did not detect OGT-
mediated GAPDH O-GlcNAcylation under our experimental
conditions. We are currently identifying NleB-mediated O-
GlcNAcylation site(s) on GAPDH to clarify the precise mecha-
nism bywhichGAPDH functions in the NF-kB signaling pathway.
We have considered the possibility that NleB activity
could be somehow coordinatedwith changes to host cell metab-
olism associated with infection (Borregaard and Herlin, 1982;
Cramer et al., 2003). However, our preliminary efforts to address
this complex issue indicated that NleB-mediated GAPDH O-
GlcNAcylation is largely insensitive to different glucose con-
centrations, likely due to the maintenance of relatively high
concentrations of UDP-GlcNAc. Therefore, NleB does not
appear to share the same mechanism as OGT, which, bywith NleB, TRAF2, and GAPDH plasmids for 60 hr and treated with 20 mM
LAG or GAPDH-Myc. Cell lysates were also immunoblotted for total protein
-GlcNAc. GAPDH O-GlcNAcylation was analyzed using a-GlcNAc antibody.
rightmost lanes of the ‘GAPDH’ and ‘NleB’ gels served as loading controls and
mples were analyzed using SDS-PAGE and immunoblotted with a-GlcNAc and
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Figure 6. NleB O-GlcNAc Transferase Activity Is Essential for Inhib-
iting the NF-kB Pathway
(A) TRAF2-His was coupled to Ni-NTA beads and then incubated with NleB-
FLAG and GAPDH. UDP-GlcNAc (1 mM) was added where indicated. Bound
and flowthrough (FT) proteins were stained with IRDye Blue.
(B) O-GlcNAcylation of free (FT) and TRAF2-associated GAPDH. Samples
were immunoblotted using a-GlcNAc antibody.
(C) ELISA plates were coated with 2 mg of either unmodified GAPDH or GAPDH
that had been labeled in vitro by O-GlcNAc after incubation with NleB and
UDP-GlcNAc. Coated plates were overlaid with increasing amounts of
TRAF2 ± 100 mM UDP-GlcNAc. Protein binding was detected using a-TRAF2
antibody (mean ± SEM, n = 4).
(D) Immunoblotting of IkBa and p65 nuclear translocation in the presence of
NleB(D202).
(E) NF-kB luciferase activity (mean ± SEM, n = 4) ± NleB and TMG. HeLa cells
were cotransfected with luciferase reporters and NleB-HA or control plasmids
for 60 hr, and treated with TMG for 8 hr before treating with TNF for 20 s.
Asterisks indicate significantly different luciferase activity, t test.
(F) AP-1 luciferase activity (mean ± SEM, n = 4) ± NleB and TMG.
(G) Colonization (log10 CFUs / g colon) of indicated C. rodentium strains
(7 days postgavage) in C57BL/6J mice (n = 6–7). Asterisks indicate signifi-
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2011). However, inhibiting OGA with TMG augmented GAPDH
O-GlcNAcylation by NleB, leaving open the possibility that
NleB coordinately regulates protein O-GlcNAcylation in concert
with the mammalian enzymes OGT and OGA.
Clostridial toxins glucosylate and inhibit GTPases of the Rho
and Ras superfamily (Kelly and LaMont, 2008). Legionella pneu-
mophila Lgt proteins glucosylate the eukaryotic elongation factor
1A to block protein synthesis (Belyi et al., 2006). Like NleB, these
toxins all belong to GT-A family of glycosyltransferases and
contain at least one Rossmann-like fold and the DXD catalytic
motif. We have yet to characterize the substrate specificity of
NleB, and it is possible that NleB may be able to utilize other
nucleotide sugars to glycosylate GAPDH. It remains to be deter-
mined if NleB interacts with other host proteins, and if so,
whether NleB O-GlcNAcylates these proteins. We note that
several other proteins detected in GAPDH immunoprecipitates
appear to be more heavily O-GlcNAcylated in the presence,
rather than in the absence, of NleB (Figure 5D).
The difference in colonization magnitude between the DnleB
strain and DnleB/pnleB(AAA) is not unexpected. NleB contains
an additional DAD motif in its N terminus, which could also
contribute to the ability of NleB to control TNF-induced NF-kB
activity. It will be interesting to examine the contribution of other
NleB functional domains to bacterial virulence. It is also possible
that NleB has functions that are independent of its glycosyltrans-
ferase activity and its targeting of the NF-kB pathway.
The impact of NleB on NF-kB is tightly linked with its O-
GlcNAc transferase activity directed against GAPDH. GAPDH
fails to interact with TRAF2 in the presence of NleB, resulting in
attenuated TRAF2 polyubiquitination. This is similar to the
phenotype of cells expressing GAPDH C150S, which also fails
to bind TRAF2 and fails to promote TRAF2 polyubiquitination.
Furthermore, the NleB(AAA) mutant is unable to O-GlcNAcylate
GAPDH and does not inhibit NF-kB activation. Our discovery
that NleB utilizes UDP-GlcNAc to disrupt TRAF2 complex forma-
tion represents a mechanism by which enteric pathogens inhibit
host innate immunity.EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, Reagents, and Oligonucleotides
Reagents were used according to manufacturers’ recommendations and are
described in the Supplemental Information. Bacterial strains, plasmids, and
oligonucleotide sequencesarealsodescribed in theSupplemental Information.
RNA Interference
Three picomoles of scrambled siRNAs or siRNAs directed against GAPDH
were transfected into HeLa cells using Lipofectamine 2000. The transfection
mixture was replaced with complete growth media after 6 hr, and cells were
incubated for a further 60 hr prior to harvest. Knockdown specificity was
confirmed using immunoblotting. GAPDH siRNA sense-strand sequencescantly different colonization magnitude as compared with WT; Kruskal-
Wallis test.
(H) NF-kB luciferase activity as a function of C. rodentium infection and
GAPDH-Myc overexpression (mean ± SEM, n = 4). HeLa cells were co-
transfected with GAPDH-Myc or Myc-epitope control plasmids with NF-kB
luciferase reporter plasmids for 48 hr and then infected with the indicated
C. rodentium strains for 3 hr. Asterisks indicate significantly different luciferase
activity between GAPDH-Myc or Myc-epitope transfection.
nc.
Figure 7. Working Model for the Role of
GAPDH in the NF-kB Signaling Pathway
and Its Targeting by NleB to Attenuate
TRAF2 Activation
After TNF stimulation through TNFR, GAPDH is
induced to the TRAF2 complex, promoting TRAF2
polyubiquitination and activating the NF-kB
pathway through IKK. Drug treatments and
mutagenesis studies show that this recruitment is
dependent upon GAPDH enzyme activity. During
infection, NleB binds GAPDH and modifies it with
O-GlcNAc. O-GlcNAcylated GAPDH is unable to
bind TRAF2, reducing downstream NF-kB acti-
vation. NleB(AAA) is deficient in O-GlcNAc trans-
ferase activity and unable to inhibit GAPDH
binding to TRAF2. Whether NleB directly impacts
host cell metabolic pathways and the identification
of other substrates for its O-GlcNAcylation activity
remains to be determined.
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NleB Glycosylates GAPDH to Inhibit TRAF2/NF-kBwere as follows: UTR-1, 50-AGCACA2GAG2A2GAGAGAGAC3T; UTR-2, 50-
CATGTAC2ATCA2UA3GTAC3TG; UTR-3, CTC2TCACAGT2GC2ATGTAGA3.
Affinity Columns and Protein Identification by LC-ESI-MS/MS
Both affinity column and mass spectrometry experiments were conducted
essentially as described before (Gao et al., 2009). Bands excised from protein
gels were digested in gel with trypsin at 37Covernight. Spectra were obtained
in the positive ion mode with a nano ESI-Q-Tof micro mass spectrometer.
In Vitro Pull-Down Assays
Purified NleB-FLAG or NleC-FLAG (1.0 mg) was immobilized on FLAG
M2-conjugated beads and then incubated with 1.0 mg GAPDH for 4 hr at
4C. Beads were centrifuged and washed three times with 20 mM HEPES
(pH 7.9), 150 mM KCl, 0.2 mM EDTA, 0.1% NP-40, 10% glycerol, 1.0 mM
DTT. SDS-PAGE sample buffer was added, and samples were analyzed using
immunoblotting.
O-GlcNAcylation Assays
NleB-FLAG or NleC-FLAG proteins (500 ng) were incubated with 500 ng
GAPDH at 4C for 18 hr ± 1 mM UDP-GlcNAc. O-GlcNAcylated proteins
were detected using the Click-iT O-GlcNAc Enzymatic Labeling System (Invi-
trogen). Alternatively, proteins were incubated in 50 mM Tris-HCl (pH 7.5),
1 mM DTT, 10 mM MnCl2, 1 mM UDP-GlcNAc for 4 hr at room temperature.
GAPDH Enzyme Activity
GAPDH activity in HeLa cells was measured by using a fluorescence-based
assay kit (KDalert GAPDH) according to the manufacturer’s recommenda-
tions. Briefly, 1.0*104 cells were treated in ±10 mM IA for 40 s. Cells were resus-
pended in ice-cold Cell Lysis Buffer and incubated for 20 s. Aliquots were
transferred to 96-well plates and changes in fluorescence were measured
every 4 s in a fluorescence plate reader. GAPDH activity was determined
through comparison to protein standards. For in vitro GAPDH enzymatic
activity assays, 0.1 mg GAPDH was preincubated with 0.1 mg NleB-FLAG or
NleC-FLAG with 1 mM IA and or 0.1 mM UDP-GlcNAc.Cell Host & Microbe 13, 87–9Luciferase Assays
Luciferase assays were conducted as described
(Gao et al., 2009). HeLa cells were cotransfected
at a ratio of 10:1 (1.0 mg total DNA) with a luciferase
reporter construct (NF-kB or AP-1) together with
the renilla luciferase pTKRL plasmid, cultured for
48 hr, in the presence or absence of TNF. Cells
were lysed with passive lysis buffer and lysates
were analyzed according to the protocol from
Dual-Luciferase Kit. The fold induction was
calculated as [relative FU stimulated]/[relative FU
unstimulated] samples. Luciferase assays wereperformed in triplicate with at least three independently transfected cell
populations.
TRAF2 Ubiquitination Assay
Ubiquitination assays were performed using enzymes obtained from Boston
Biochem, supplemented with NleB (50 nM) and UDP-GlcNAc (1 mM).
His-E1(100 nM), Ubc/Uev1a (100 nM), His-TRAF2 (50 nM), ubiquitin (2 mM),
and ATP (2 mM) were incubated in 5 mM MgCl2, 50 mM HEPES (pH 7.5),
10 mMNaCl, 1 mMDTT at 30C for 1 hr, in the presence or absence of GAPDH
(50 nM), NleB (50 nM), and UDP-GlcNAc (1mM). Reactions were terminated by
adding SDS-PAGE loading buffer and boiled at 95C for 50. TRAF2 ubiquitina-
tion was determined using immunoblotting with a-ubiquitin antibody.
ELISAs
TNF concentrations in mouse sera were measured using a mouse TNF Quan-
tikine ELISA Kit according to the manufacturer’s instructions. Protein binding
studies were conducted as previously described (Pham et al., 2012).
Mouse Infections
All animal experiments were performed according to Institutional Animal Care
and Use Committee-approved protocols (Animal Welfare Assurance #A3237-
01) and conducted as previously described (Gao et al., 2009).
Bioinformatics
Probabilistic searches using profile Hidden Markov Models were done using
the HHPred/HHSearch package (So¨ding et al., 2005). Multiple sequence align-
ments were obtained using the PROMALS3D software (Pei et al., 2008),
seeded with NleB and their glycogenin-related homologs.
Statistics
RT-PCR, luciferase, ELISA, and enzyme activity data were analyzed statisti-
cally using one-way ANOVA with Bonferonni’s multiple comparison tests.
C. rodentium colonization data were analyzed using the Kruskal-Wallis test.
p values < 0.05 were considered significant.9, January 16, 2013 ª2013 Elsevier Inc. 97
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